Also, time staggered delivery, simultaneous delivery or a sequential application of anti-CD24 treatment and cisplatin delivery can further help understand the mechanics of CD24 expression and cisplatin resistance in HNSCC tumors in vivo. Here, CD24 is linked to head and neck squamous cell carcinoma.